Saxagliptin (BMS-477118)

Catalog No.S1540 Synonyms: Onglyza

For research use only.

Saxagliptin (BMS-477118, Onglyza) is a selective and reversible DPP4 inhibitor with IC50 of 26 nM.

Saxagliptin (BMS-477118) Chemical Structure

CAS No. 361442-04-8

Selleck's Saxagliptin (BMS-477118) has been cited by 5 Publications

1 Customer Review

Purity & Quality Control

Choose Selective DPP Inhibitors

Other DPP Products

Biological Activity

Description Saxagliptin (BMS-477118, Onglyza) is a selective and reversible DPP4 inhibitor with IC50 of 26 nM.
DPP-4 [1]
26 nM
In vitro

Saxagliptin has an inhibition constant Ki of 1.3 nM for DPP4 inhibition, which is 10-fold more potent than either vildagliptin or sitagliptin (another two DPP4 inhibitors) with Ki of 13 and 18 nM. In addition, Saxagliptin demonstrates greater specificity for DPP4 than for either the DPP8 or DPP9 enzymes (400- and 75- fold, respectively). The active metablite of saxagliptin is two-fold less potent than the parent. Both Saxagliptin and its metabolite are highly selective (>4000-fold) for the prevention of DPP4 compared with a range of other proteases (selectivity of sitagliptin and vildagliptin for DPP4 is >2600 and <250-fold, respectively, compared with DPP8 and DPP9). [2] Saxagliptin reduces the degradation of the incretin hormone glucagon-like peptide-1, thereby enhancing its actions, and is associated with improved β-cell function and suppression of glucagon secretion. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Caco-2 cells MmrYSpVv[3Srb36gZZN{[Xl? Mnq1TY5pcWKrdHnvckBw\iCqdX3hckBFWFB2IHX4dJJme3OnZDDpckBE[WOxLUKgZ4VtdHNuIFvpQVAvPiCwTR?= NVvaW5pXOTdyM{SxOFg>
In vivo Maximal responses of Saxagliptin in glucose excursion in Zuckerfa/fa rats are associated with plasma DPP4 inhibition of approximately 60% vs. control, and no additional antihyperglycemic effects are seen at higher percent inhibition. Saxagliptin is highly effective at eliciting marked dose-dependent enhancements in glucose clearance in the dose range 0.13-1.3 mg/kg in ob/ob mice relative to controls. Saxagliptin dose-dependently elevate plasma insulin significantly at 15 min post-oGTT, with concomitant improvement in the glucose clearance curves at 60 min post-oGTT. [4]

Protocol (from reference)

Animal Research:[4]
  • Animal Models: Male 13−14 week-old ob/ob mice
  • Dosages: 10 μmol/kg
  • Administration: Orally

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
For best results, use promptly after mixing.

30 mg/mL

Chemical Information

Molecular Weight 315.41


CAS No. 361442-04-8
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1C2CC2N(C1C#N)C(=O)C(C34CC5CC(C3)CC(C5)(C4)O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04445714 Recruiting Drug: dapagliflozin and saxagliptin Type 2 Diabetes Mellitus AstraZeneca April 7 2021 Phase 4
NCT04521049 Completed Drug: Saxagliptin 5mg Diabetes Mellitus Type 2 Beni-Suef University March 1 2019 Phase 4
NCT02462369 Unknown status Drug: Saxagliptin|Drug: glimepiride Microalbuminuria|Microalbuminuria /Creatinine Ratios ACR The Second Hospital of Nanjing Medical University June 2015 Phase 4
NCT02280486 Completed Drug: Saxagliptin|Drug: Glimepiride Type 2 Diabetes The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|The First Affiliated Hospital with Nanjing Medical University|Zhongda Hospital|Nanjing PLA General Hospital|Changzhou No.2 People''s Hospital|The First Affiliated Hospital of Soochow University|Wuxi People''s Hospital|The First Affiliated Hospital of Anhui Medical University|Huai''an First People''s Hospital January 2015 Phase 4

(data from, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Saxagliptin (BMS-477118) | Saxagliptin (BMS-477118) supplier | purchase Saxagliptin (BMS-477118) | Saxagliptin (BMS-477118) cost | Saxagliptin (BMS-477118) manufacturer | order Saxagliptin (BMS-477118) | Saxagliptin (BMS-477118) distributor